News and Trends 2 Nov 2016 Antibody Therapies are here to Revolutionize Dermatology Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […] November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2016 This Technology could Open Up a new 4th Generation of Therapeutic Antibodies From everyday immunostaining to billion-euro therapies, antibodies have become essential in Biotech. Selecting the right antibodies that are as close to human as possible minimizes risks and can be the key to success, especially in medical applications. What goes into making the best therapeutic antibodies? To answer this question, we sat down with BIOTEM, an experienced provider of custom […] November 1, 2016 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […] October 31, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […] October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer. The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of […] October 28, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2016 UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies Crescendo Biologics, a small UK-based startup, has made an almost €1B deal with Japanese giant Takeda for its Humabody technology. Crescendo Biologics may seem like a small fish, but it has caught the attention of a host of blue-chip investors like Sofinnova Partners. Its Humabody platform has recently attracted the Japanese pharmaceutical giant, Takeda, whose subsidiary, […] October 11, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2016 Researchers Find New Weak Spots to Develop an HIV Cure Last week we published a thorough review on current approaches for an HIV cure, which may be available as soon as 2020. Academia has come up with two additional strategies that could make a huge difference in the study of HIV. HIV affects 36.7 million people in the world and caused 1.1 million deaths last year. Plenty of resources […] October 3, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email